Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing other research and early-stage development programs. It markets KALYDECO to treat patients of six years of age and older with CF who have specific genetic mutations in their cystic fibrosis transmembrane conductance (CFTR) regulator gene in the United States, European Union, and Canada. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. In addition, it is developing Ivacaftor in combination with CFTR corrector compounds, which has completed Phase III development program; and evaluating VX-661, a second investigational CFTR corrector, in combination with ivacaftor in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. Further, it is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. The company sells its products principally to major and selected regional wholesalers and specialty pharmacy providers in North America, as well as government-owned and supported customers in Europe. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Country: United States
Is shortable: Yes
|Long position||Short position|
Temporary margin requirements due to upcoming corporate events:Margin Calendar